ProMIS Neurosciences to Report Q3 Results Nov. 12
Shareholders and analysts tracking ProMIS will get its third quarter update and corporate news at an investor call that day.
Updated on Nov. 3, 2026 in Corporate Finance
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company, will report its third quarter 2026 financial results on November 12, 2026, covering the period ended September 30, 2026. The company will also provide corporate updates alongside the results, which matter to investors and operators tracking small-cap biotech disclosure cadence.
Why it matters
Quarterly reporting and an accompanying investor call are routine disclosure steps for publicly traded clinical-stage companies, giving shareholders and analysts a scheduled point to assess progress. The timing is set in advance, so the update is a known, forecastable event rather than an unexpected development.
The third quarter 2026 reporting period ends September 30, 2026, and the investor conference call starts at 4:30 p.m. ET on November 12, 2026. The extraction did not include any financial figures or prior-period comparators for the quarter.
The players
ProMIS Neurosciences Inc. (Nasdaq: PMN)
A clinical-stage biotechnology company developing treatments for neurodegenerative disease, listed on Nasdaq and headquartered in Cambridge, Massachusetts, with a secondary office in Toronto, Ontario.
The details
ProMIS will hold an investor conference call and webcast on November 12, 2026, at 4:30 p.m. Eastern Time, where it will discuss its third quarter results and corporate updates. A replay of the webcast will be posted in the Investors section of the company's website after the call ends. The company has also published an investor Q&A on the scientific rationale for its PMN310 program, which gives shareholders background ahead of the results.
Timeline
September 30, 2026: Third quarter 2026 reporting period ends.
November 3, 2026: ProMIS announces the date of its third quarter results.
November 12, 2026: Third quarter results are released and the investor conference call takes place at 4:30 p.m. ET.
Market Landscape
Quarterly results and scheduled investor calls are the standard disclosure rhythm for U.S.-listed companies under SEC periodic-reporting rules. For a clinical-stage biotech on Nasdaq, the November update is one of the few scheduled points where shareholders can compare pipeline progress against the prior quarter.
Investors and analysts tracking ProMIS should calendar the November 12 call and review the third quarter results and corporate updates when released. Those monitoring small-cap biotech peers can use the scheduled release as a benchmark for how the company frames pipeline progress and cash position.
The takeaway
For operators and finance teams, the practical signal is the scheduled cadence: a fixed earnings date and call give a predictable window to review disclosures. Calendar the November 12 call and compare the reported figures against the September 30 period when results post.
What happens next
ProMIS will report its third quarter 2026 financial results and host the investor conference call on November 12, 2026, at 4:30 p.m. ET.
Further reading
For context on how quarterly disclosures like this one fit into broader company reporting, see Corporate Finance coverage.
